Russian Journal of Pediatric Surgery, Anesthesia and Intensive CareRussian Journal of Pediatric Surgery, Anesthesia and Intensive CareРоссийский вестник детской хирургии, анестезиологии и реаниматологии2219-40612587-6554Eco-Vector99910.17816/psaic999DiscussionsДискуссииShort CommunicationReply to the Commentary on the article “Sepsis in children: federal guidelines (draft)” I.А. SavinОтвет на Комментарий к статье «Сепсис у детей: федеральные клинические рекомендации (проект)» И.А. Савинаhttps://orcid.org/0000-0003-0798-16253630-5061LekmanovAndrey U.ЛекмановАндрей Устинович
Russian Federation

Dr. Sci. (Med.), Professor

д-р мед. наук, профессор

aulek@rambler.ruhttps://orcid.org/0000-0003-1473-19826694-6714PopovDmitry А.ПоповДмитрий Александрович
Russian Federation

Dr. Sci. (Med.)

д-р мед. наук

da_popov@inbox.ruPirogov Russian Research Medical UniversityРоссийский научно-исследовательский медицинский университет им. Н.И. ПироговаBakulev National Medical Research Center for Cardiovascular SurgeryНациональный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева131020211134134160909202109092021Copyright ©; 2021, Lekmanov A.U., Popov D.А.Copyright ©; 2021, Лекманов А.У., Попов Д.А.2021Lekmanov A.U., Popov D.А.Лекманов А.У., Попов Д.А.https://creativecommons.org/licenses/by-nc-nd/4.0https://rps-journal.ru/jour/article/view/999

The authors of the Clinical Guidelines are grateful to Professor I.A. Savin for his comments and provide answers to the comments made regarding the appointment of antibacterial drugs and immunoglobulins for sepsis in children.

Авторы Клинических рекомендаций благодарят профессора И.А. Савина за его комментарии и приводят ответы на высказанные замечания, касающиеся назначения антибактериальных препаратов и иммуноглобулинов при сепсисе у детей.

sepsisclinical guidelineschildrenсепсисклинические рекомендациидетиWeiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign International Guidelines for the Management Sepsis and Septic Shock and Sepsis-associated Organ Dysfunction in Children. Pediatr Crit Care Med. 2020;21(2):e52–e106. DOI: 10.1097/PCC.0000000000002198Weiss S.L., Peters M.J., Alhazzani W., et al. Surviving Sepsis Campaign International Guidelines for the Management Sepsis and Septic Shock and Sepsis-associated Organ Dysfunction in Children // Pediatr Crit Care Med. 2020. Vol. 21. No. 2. P. e52–e106. DOI: 10.1097/PCC.0000000000002198El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, Boshra N. Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. J Trop Pediatr. 2005;51(5):271-278. DOI: 10.1093/tropej/fmi011El-Nawawy A., El-Kinany H., Hamdy El-Sayed M., Boshra N. Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit // J Trop Pediatr. 2005. Vol. 51. No. 5. P. 271–278. DOI: 10.1093/tropej/fmi011Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. 2013;(7):CD001239. DOI: 10.1002/14651858.CD001239.pub4. Corrected and republished from: Cochrane Database Syst Rev. 2015;(3):CD001239. DOI: 10.1002/14651858.CD001239.pub5Ohlsson A., Lacy J.B. Intravenous immunoglobulin for suspected or proven infection in neonates // Cochrane Database Syst Rev. 2013. Vol. 2. No. 7. P. CD001239. DOI: 10.1002/14651858.CD001239.pub4. Corrected and republished from: Cochrane Database Syst Rev. 2015. No. 3. P. CD001239. DOI: 10.1002/14651858.CD001239.pub5INIS Collaborative Group; Brocklehurst P, Farrell B, King A, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med. 2011;365(13):1201–1211. DOI: 10.1056/NEJMoa1100441INIS Collaborative Group; Brocklehurst P., Farrell B., King A., et al. Treatment of neonatal sepsis with intravenous immune globulin // N Engl J Med. 2011. Vol. 29, No. 365(13). P. 1201–1211. DOI: 10.1056/NEJMoa1100441Beloborodova NV, Popov DA, Shatalov KV, et al. Zamestitel’naja immunoterapija pod kontrolem testa na prokal’citonin – novyj podhod k preduprezhdeniju manifestacii infekcii v posleoperacionnom periode u detej so slozhnymi vrozhdennymi porokami serdca. Heart and Vessels Diseases in Children. 2005;3:62–68. (In Russ.)Белобородова Н.В., Попов Д.А., Шаталов К.В., и др. Заместительная иммунотерапия под контролем теста на прокальцитонин — новый подход к предупреждению манифестации инфекции в послеоперационном периоде у детей со сложными врожденными пороками сердца // Детские болезни сердца и сосудов. 2005. Т. 3. С. 62–68.Abdullayev E, Kilic O, Bozan G, et al. Clinical, laboratory features and prognosis of children receiving IgM-enriched immunoglobulin (3 days vs. 5 days) as adjuvant treatment for serious infectious disease in pediatric intensive care unit: a retrospective single-center experience (PIGMENT study). Human Vaccines & Immunotherapeutics. 2020;16(8):1997–2002. DOI: 10.1080/21645515.2019.1711298Abdullayev E., Kilic O., Bozan G., et al. Clinical, laboratory features and prognosis of children receiving IgM-enriched immunoglobulin (3 days vs. 5 days) as adjuvant treatment for serious infectious disease in pediatric intensive care unit: a retrospective single-center experience (PIGMENT study). Human Vaccines & Immunotherapeutics. 2020. Vol. 16. No. 8. P. 1997–2002. DOI: 10.1080/21645515.2019.1711298Martinez J-I, Sánchez H-F, Velandia J-A, et al. Treatment with IgM-enriched immunoglobulin in sepsis: a matched case-control analysis. J Crit Care. 2021;64:120–124. DOI: 10.1016/j.jcrc.2021.03.015Martinez J.-I., Sánchez H.-F., Velandia J.-A., et al. Treatment with IgM-enriched immunoglobulin in sepsis: a matched case-control analysis // J Crit Care. 2021. Vol. 64. P. 120–124. DOI: 10.1016/j.jcrc.2021.03.015